Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 110 Intravaroros Road, A. Muang, Chiang Mai, 50200, Thailand.
Lerdsin Hospital, Bangkok, Thailand.
BMC Nephrol. 2020 Aug 3;21(1):325. doi: 10.1186/s12882-020-01990-8.
Cardiorenal syndrome (CRS), a serious condition with high morbidity and mortality, is characterized by the coexistence of cardiac abnormality and renal dysfunction. There is limited information about CRS in association thalassemia. This study aimed to investigate the prevalence of CRS in thalassemia patients and also associated risk factors.
Thalassemia patients who attended the out-patient clinic of a tertiary care university hospital from October 2016 to September 2017 were enrolled onto this cross-sectional study. Clinical and laboratory findings from 2 consecutive visits, 3 months apart, were assessed. The criteria for diagnosis of CRS was based on a system proposed by Ronco and McCullough. Cardiac abnormalities are assessed by clinical presentation, establishment of acute or chronic heart failure using definitions from 2016 ESC guidelines or from structural abnormalities shown in an echocardiogram. Renal dysfunction was defined as chronic kidney disease according to the 2012 KDIGO guidelines.
Out of 90 thalassemia patients, 25 (27.8%) had CRS. The multivariable analysis showed a significant association between CRS and extramedullary hematopoiesis (EMH) (odds ratio (OR) 20.55, p = 0.016); thalassemia type [β/β vs β/β thalassemia (OR 0.005, p = 0.002)]; pulmonary hypertension (OR 178.1, p = 0.001); elevated serum NT-proBNP (OR 1.028, p = 0.022), and elevated 24-h urine magnesium (OR 1.913, p = 0.016). There was no association found between CRS and frequency of blood transfusion, serum ferritin, liver iron concentration, cardiac T2*, type of iron chelating agents, or urine neutrophil gelatinase-associated lipocalin level.
CRS is relatively common in thalassemia patients. Its occurrence is associated with laboratory parameters which are easily measured in clinical practice.
心肾综合征(CRS)是一种发病率和死亡率均较高的严重疾病,其特征为心脏异常和肾功能障碍同时存在。关于地中海贫血相关 CRS 的信息有限。本研究旨在调查地中海贫血患者中 CRS 的患病率及相关危险因素。
本横断面研究纳入了 2016 年 10 月至 2017 年 9 月期间在一家三级大学医院门诊就诊的地中海贫血患者。评估了两次连续就诊(间隔 3 个月)的临床和实验室检查结果。CRS 的诊断标准基于 Ronco 和 McCullough 提出的系统。心脏异常通过临床表现、根据 2016 年 ESC 指南或超声心动图显示的结构异常确定急性或慢性心力衰竭来评估。根据 2012 年 KDIGO 指南,肾功能障碍定义为慢性肾脏病。
在 90 例地中海贫血患者中,有 25 例(27.8%)患有 CRS。多变量分析显示,CRS 与髓外造血(EMH)(比值比(OR)20.55,p=0.016)、地中海贫血类型[β/β 与β/β 地中海贫血(OR 0.005,p=0.002)]、肺动脉高压(OR 178.1,p=0.001)、血清 NT-proBNP 升高(OR 1.028,p=0.022)和 24 小时尿镁升高(OR 1.913,p=0.016)显著相关。CRS 与输血频率、血清铁蛋白、肝铁浓度、心脏 T2*、铁螯合剂类型或尿液中性粒细胞明胶酶相关脂质运载蛋白水平无相关性。
CRS 在地中海贫血患者中较为常见。其发生与临床实践中易于测量的实验室参数相关。